Search Results

You are looking at 91 - 100 of 1,744 items for :

  • "chemotherapy" x
Clear All
Full access

Jeffrey A. Gilreath, Daniel S. Sageser, James A. Jorgenson and George M. Rodgers

. Auerbach M Ballard H Trout JR . Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial . J Clin Oncol 2004 ; 22 : 1301 – 1307

Full access

George M. Rodgers

Cancer- and Chemotherapy-Induced Anemia during its early years and have chaired it since 2004. Major changes in the NCCN Guidelines on anemia over the years have focused on 2 topics: erythropoiesis-stimulating agent (ESA) safety and the increasing use of

Full access

Jacob P. Laubach, Constantine S. Mitsiades, Anuj Mahindra, Robert L. Schlossman, Teru Hideshima, Dharminder Chauhan, Nicole A. Carreau, Irene M. Ghobrial, Noopur Raje, Nikhil C. Munshi, Kenneth C. Anderson and Paul G. Richardson

Anderson H Scarffe JH Ranson M . VAD chemotherapy as remission induction for multiple myeloma . Br J Cancer 1995 ; 71 : 326 – 330 . 19 Alexanian R Barlogie B Dixon D . High dose glucocorticoid treatment of resistant myeloma . Ann Intern Med

Full access

S. Machele Donat

cancer . J Clin Oncol 2005 ; 23 : 4602 – 4608 . 10 Schultz PK Herr HW Zhang ZF . Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up . J Clin Oncol

Full access

Rudolph M. Navari

of the side effects of chemotherapy: the influence of the 5HT 3 antagonists . Br J Cancer 1997 ; 76 : 1055 – 1061 . 2. Lachaine J Yelle L Kaizer L . Chemotherapy-induced emesis: quality of life and economic impact in the context of

Full access

Pamala A. Pawloski, Gabriela Vazquez-Benitez, Jeanette Y. Ziegenfuss, Terese A. DeFor and Elisabeth M. Seburg

Background: Older patients diagnosed with colorectal cancer are not routinely included in clinical trials and are frequently treated with less aggressive chemotherapy. To identify factors associated with treatment initiation in older adults, we

Full access

David C. Dale, Gordon C. McCarter, Jeffrey Crawford and Gary H. Lyman

results of 20 years of follow-up . N Engl J Med 1995 ; 332 : 901 – 906 . 2 Wood WC Budman DR Korzun AH . Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma . N Engl J Med 1994 ; 330 : 1253

Full access

Robert W. Carlson, Susan J. Moench, M. Elizabeth H. Hammond, Edith A. Perez, Harold J. Burstein, D. Craig Allred, Charles L. Vogel, Lori J. Goldstein, George Somlo, William J. Gradishar, Clifford A. Hudis, Mohammad Jahanzeb, Azadeh Stark, Antonio C. Wolff, Michael F. Press, Eric P. Winer, Soonmyung Paik, Britt-Marie Ljung and for the NCCN HER2 Testing in Breast Cancer Task Force

, although other HER2-targeted agents are under study. The precise mechanisms of action of trastuzumab are unknown, 41 but very recent studies have provided insight into one way in which trastuzumab, in combination with chemotherapy, may act as a cytotoxic

Full access

Richard I. Fisher

/doxorubicin/vincristine/prednisone] vs mAb/bendamustine), and now, chemotherapy-free treatment with targeted agents. Chemotherapy-free treatment can be considered as a first-line treatment option for FL, but only in selected patients, Dr. Fisher emphasized. “I would argue that rituximab

Full access

Siu-Fun Wong, Mark Bounthavong, Cham P. Nguyen and Timothy Chen

Background Historically, patients with cancer primarily receive intravenous anticancer chemotherapy and are monitored for efficacy, side effects, and adherence in the supervised setting of an infusion clinic. Approximately 25% of 400 novel